Design, synthesis and pharmacological evaluation of caffeic acid phenethyl ester acylation as multifunctional neuroprotective agents against oxidative stress injury

doi:10.5246/jcps.2013.06.069

Journal of Chinese Pharmaceutical Sciences

• Original articles • Previous Articles Next Articles

Design, synthesis and pharmacological evaluation of caffeic acid phenethyl ester acylation as multifunctional neuroprotective agents against oxidative stress injury

Renzong Zhu, Xianling Ning, Zhili Zhang, Xiaowei Wang, Chao Tian, Junyi Liu^*

Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2013-06-03 Revised:2013-06-15 Online:2013-11-15 Published:2014-01-22
Contact: Junyi Liu*

Abstract

Abstract:

4-Acylated or 3,4-diacylated caffeic acid phenethyl ester (CAPE) was prepared as prodrug to improve its stability and lipid solubility. Their neuroprotective activities were assessed by H2O2 model and 6-OHDA model. The results showed that target compounds displayed positive abilities to protect PC12 nerve cells from oxidative stress injury, superior to that of CAPE. Additionally, target compounds showed high blood-brain barrier permeability.

Key words: Amyotrophic lateral sclerosis, Acylation, Caffeic acid phenethyl ester, Neuroprotective agents, Blood-brain barrier permeability

CLC Number:

R916

Supporting:

Renzong Zhu, Xianling Ning, Zhili Zhang, Xiaowei Wang, Chao Tian, Junyi Liu^*. Design, synthesis and pharmacological evaluation of caffeic acid phenethyl ester acylation as multifunctional neuroprotective agents against oxidative stress injury[J]. Journal of Chinese Pharmaceutical Sciences, DOI: 10.5246/jcps.2013.06.069.

References

[1] Blaauw, R.; Labadarios, D. SADJ. 2000, 55, 327-328.
[2] Andersen, P.M.; Sims, K.B.; Xin, W.W.; Kiely, R.; O'Neill, G.; Ravits, J.; Pioro, E.; Harati, Y.; Brower, R.D.; Levine, J.S. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2003, 4, 62-73.
[3] Zagami, C.J.; Beart, P.M.; Wallis, N.; Nagley, P.; O’Shea, R.D. Glia. 2009, 57, 119-135.
[4] Pasinelli, P.; Brown, R.H. Nat. Rev. Neurosci. 2006, 7, 710-723.
[5] Chen, Y.J.; Shiao, M.S.; Wang, S.Y. Anticancer Drugs. 2001, 12, 143-149.
[6] Orban, Z.; Mitsiades, N.; Burke, T.R.J.; Tsokos, M.; Chrousos, G.P. Neuroimmunomodulation. 2000, 7, 99-105.
[7] Fesen, M.R.; Kohn, K.W.; Leteurtre, F.; Pommier, Y. Proc. Natl. Acad. Sci. USA. 1993, 90, 2399-2403.
[8] Kujumgiev, A.; Bankova, V.; Ignatova, A.; Popov, S. Pharmazie. 1993, 48, 785-786.
[9] Natarajan, K.; Singh, S.; Burke, T.R.J.; Grunberger, D.; Aggarwal, B.B. Proc. Natl. Acad. Sci. USA. 1996, 93, 9090-9095.
[10] Lefkovits, I.; Su, Z.; Fisher, P.; Grunberger, D. Int. J. Oncol. 1997, 11, 59-67.
[11] Grunberger, D.; Banerjee, R.; Eisinger, K.; Oltz, E.M.; Efros, L.; Caldwell, M.; Estevez, V.; Nakanishi, K. Experientia. 1988, 44, 230-232.
[12] Sudina, G.F.; Mirzoeva, O.K.; Pushkareva, M.A.; Korshunova, G.A.; Sumbatyan, N.V.; Varfolomeev, S.D. FEBS Lett. 1993, 329, 21-24.
[13] Ma, Z.; Wei, X.; Fontanilla, C.; Noelker, C.; Dodel, R.; Hampel, H.; Du, Y. Life Sci. 2006, 79, 1307-1311.
[14] Wei, X.; Ma, Z.; Fontanilla, C.V.; Zhao, L.; Xu, Z.C.; Taggliabraci, V.; Johnstone, B.H.; Dodel, R.C.; Farlow, M.R.; Du, Y. Neuroscience. 2008, 155, 1098-1105.
[15] Wei, X.; Zhao, L.; Ma, Z.; Holtzman, D.M.; Yan, C.; Dodel, R.C.; Hampel, H.; Oertel, W.; Farlow, M.R.; Du, Y. Brain. 2004, 127, 2629-2635.
[16] Altug, M.E.; Serarslan, Y.; Bal, R.; Kontas, T.; Ekici, F.; Melek, I.M.; Aslan, H.; Duman, T. Brain Res. 2008, 1201, 135-142.
[17] Deng, D.; Zhang, J.; Cooney, J.M.; Skinner, M.A.; Adaim, A.; Jensen, D.J.; Stevenson, D.E. FEBS Lett. 2006, 580, 5247-5250.
[18] Sopheak, S.; Emil, B.L.; Betty, A.L. Chem. Pharm. Bull. 2001, 49, 236-238.
[19] Halleck, M.M.; Richburg, J.H.; Kauffman, F.C. Free Radic. Biol. Med. 1992, 12, 137-144.
[20] Di, L.; Kerns, E.H.; Fan, K.; McConnell, O.J.; Carter, G.T. Eur. J. Med. Chem. 2003, 38, 223-232.
[21] Wohnsland, F.; Faller, B. J. Med. Chem. 2001, 44, 923-930.
[22] Chen, X.; Murawski, A.; Patel, K.; Crespi, C.L.; Balimane, P.V. Pharm. Res. 2008, 25, 1511-1520.

Design, synthesis and pharmacological evaluation of caffeic acid phenethyl ester acylation as multifunctional neuroprotective agents against oxidative stress injury

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments

[1]	Bolin Wu, Yameng Hao, Ying Chen, Qian Liu, Chao Tian, Zhili Zhang, Junyi Liu, Xiaowei Wang. Studies on the structure-activity relationship of caffeate derivatives as neuroprotective agents [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(9): 615-626.
[2]	Yaya Zhai, Gang Yan, Wenjie Huang, Yan Niu, Fengrong Xu, Lei Liang, Chao Wang, Ping Xu. Synthetic strategies for piperazine derivatives [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(8): 572-577.
[3]	Qingzhao Liang, Hui Li, Wenxuan Zhang, Xiangbao Meng, Zhongjun Li. Scalable synthesis of salidroside [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(7): 446-453.
[4]	Zhutuo Chen, Xianling Ning, Junyi Liu^*. Synthesis of (1E)-phenyl-2-(3',4'-dihydroxyphenyl)ethenesulfonates as potent neuroprotective agents and evaluation of their activities [J]. , 2013, 22(2): 161-166.
[5]	Xian-Ling Ning, Xiao-Yan Ma^, Zhu-Tuo Chen, Ren-Zong Zhu, Chao Li, Xiao-Wei Wang, Zhi-Li Zhang, Jun-Yi Liu^. Caffeic acid phenethyl ester and its benzoyl derivatives: synthesis and X-ray structural analysis [J]. , 2011, 20(1): 37-41.
[6]	LI Shu-chun, ZHOU Jing, LI Zhong-jun^*. Synthesis of Phenylpropanoid Glycoside Analogs [J]. , 2004, 13(1): 14-18.